The prognostic importance of comorbidity for mortality in patients with stable coronary artery disease  by Sachdev, Molly et al.
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OBJECTIVES To identify the prevalent and prognostically important coexisting illnesses among single
coronary artery disease (CAD) patients.
BACKGROUND As the population ages, physicians are increasingly required to make decisions concerning
patients with multiple co-existing illnesses (comorbidity). Many trials of CAD therapy have
excluded patients with significant comorbidity, such that there are limited data to guide the
management of those patients.
METHODS To consider the long-term prognostic importance of comorbid illness, we examined a cohort
of 1,471 patients with CAD who underwent cardiac catheterization between 1985 and 1989
and were followed up through 2000 in the Duke Databank for Cardiovascular Diseases.
Weights were assigned to individual diseases according to their prognostic significance in Cox
proportional hazards models, thus creating a new CAD-specific index. The new index was
compared with the widely used Charlson index, according to prevalence of conditions,
individual and overall associations with survival, and agreement.
RESULTS The Charlson index and the CAD-specific index were highly associated with long-term
survival and almost equivalent to left ventricular ejection fraction. When considering the
components of the Charlson index, diabetes, renal insufficiency, chronic obstructive pulmo-
nary disease, and peripheral vascular disease had greater prognostic significance among CAD
patients, whereas peptic ulcer disease, connective tissue disease, and lymphoma were less
significant. Hemiplegia, leukemia, lymphoma, severe liver disease, and acquired immunode-
ficiency syndrome were rarely identified among patients undergoing coronary angiography.
CONCLUSIONS Comorbid disease is strongly associated with long-term survival in patients with CAD. These
data suggest co-existing illnesses should be measured and considered in clinical trials, disease
registries, quality comparisons, and counseling of individual patients. (J Am Coll Cardiol
2004;43:576–82) © 2004 by the American College of Cardiology Foundationd
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ms people age, they are more likely to develop chronic
edical conditions, including hypertension, vascular dis-
ase, arthritis, and cancer. Over 60% of persons 60 years
ld have two or more such chronic illnesses (1). Although
tudies of medical therapeutics typically focus on a single
isease, such co-existing illnesses can potentially alter both
he efficacy of therapies and the course of the primary
isease. With the provision of new therapies to older
atients, it has become increasingly important to understand
he impact of co-existing illness, or “comorbidity,” on
ong-term prognosis.
See page 583
In the case of patients with coronary artery disease
CAD), comorbid illness has typically been considered
ccording to two systems: “coronary disease risk factors,” or
iseases that increase the likelihood of developing coronary
isease, and the Charlson comorbidity index (2,3). The
ormer approach involving risk factors for coronary disease
From the Duke Clinical Research Institute, Duke University, Durham, North
arolina.
Manuscript received October 21, 2002; revised manuscript received September 22,f003, accepted October 7, 2003.oes not consider a number of prevalent and morbid
llnesses, including cancer, lung disease, and renal insuffi-
iency. The latter measure, the Charlson index, considers 12
hronic conditions and corresponding weights according to
heir association with one-year mortality in a cohort of 559
atients treated in the General Medicine Department of
ew York University.
In this study, we sought to identify the chronic medical
onditions that are important for CAD patients according to
heir prevalence and association with long-term mortality
mong a cohort of 1,471 patients followed up for over 10 years.
e also examined the degree to which a new CAD-specific
omorbidity index provided additional prognostic information
ompared with the widely used Charlson index.
ETHODS
atient population. All patients undergoing initial coro-
ary angiography for symptoms of chronic CAD and found
o have significant disease (75% stenosis) in one or more
oronary arteries between July 1985 and June 1989 at Duke
niversity Medical Center were identified using the Duke
atabank for Cardiovascular Diseases. Of the patients
eeting this criterion, a random 50% sample was selectedor detailed assessment of comorbid illnesses.
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February 18, 2004:576–82 CAD-Specific Comorbidity IndexRelevant coronary disease data from history and coronary
ngiography were prospectively collected as previously de-
cribed (4,5). Comorbidity information required to calculate
he Charlson index was collected by chart review, according
o the approach and definitions established by Charlson (2).
atients were followed up at six months, one year, and then
nnually by a mailed questionnaire, with telephone backup,
s well as a National Death Index search for nonresponders
hrough December 2000. Coronary disease severity was
pecified according to: 1) the number of epicardial coronary
rteries involved; 2) a previously established index of coro-
ary disease severity ranging from 0 to 100, based on the
everity and location of lesions and their relative prognostic
mportance (i.e., a 75% right coronary artery lesion would be
ated at 20; a 95% left main lesion would be rated at 100);
) and left ventricular ejection fraction (LVEF).
nalysis. We used Cox proportional hazards regression
odels, using time to all-cause mortality as the depen-
ent variable, to develop a new CAD-specific comorbid-
ty index and to compare the relative prognostic associ-
tion of the new index with the Charlson index (6,7).
AD-specific index. To consider the likely possibility that
omorbid illnesses may have different associations with
ortality for CAD patients, we entered all non-cardiac
lements (excluding myocardial infarction [MI] and con-
estive heart failure [CHF]) of the Charlson index, preva-
ent among the study population, along with tobacco abuse,
ypertension, hyperlipidemia, and family history, into a
roportional hazards model containing age, gender, LVEF,
nd CAD severity to create a CAD-specific index. Contin-
ous variables were transformed to conform to model
ssumptions. After the final model was determined, a
eight for each comorbidity component was derived using
he log hazard ratios from the model. A weight of 2 was
ssigned to diabetes, and weights for the other components
ere calculated relative to diabetes and then rounded to the
earest integer. Then, any component with a derived weight
f 0 was dropped before creating the final CAD-specific
ndex. To avoid spurious associations, the CAD-specific
odel was first developed on a training sample involving a
andom 50% of subjects and then tested on the remaining
0%. As both samples resulted in similar indexes, the final
ndex was derived for the full sample. To verify the stability
f the low prevalence conditions, bootstrap estimations were
lso done. Bootstrap samples (400 samples of the same size
s the original population, but with patients drawn ran-
omly, with replacement, from the full study population)
Abbreviations and Acronyms
AIDS  acquired immunodeficiency syndrome
CAD  coronary artery disease
CHF  congestive heart failure
LVEF  left ventricular ejection fraction
MI  myocardial infarctionere created. The model was fit on these bootstrap samples lnd then tested on the original sample to estimate the
egree to which the predictive accuracy of the model would
eteriorate when applied to an independent sample of
atients (8).
omparisons of CAD-specific index and Charlson index.
fter deriving a CAD-specific index, we compared its
ssociation with survival to that of the Charlson index.
roportional hazards models involving the same patients
ere specified, adjusting for age, gender, LVEF, CAD
everity, and either the CAD-specific index or the Charl-
on index. First, we compared the original Charlson
ndex scores with the new scores for specific conditions.
econd, model likelihood ratio chi-square values were
ompared as a reflection of the association with survival.
hird, the relative discriminatory ability of each index
as also considered by a comparison of model likelihood
atio chi-square values. Fourth, calibration was consid-
red by plotting predicted survival probability versus
ctual survival probability, stratified by 10 intervals of
redicted survival probability. Finally, to consider relative
rognostic associations when the Charlson index and
AD-specific index disagreed, we plotted Kaplan-Meier
urves for three sets of patients: those whose CAD-
pecific index scores fell within the interquartile range at
ach Charlson score (similar prediction); those whose
AD-specific index scores were above the 75th percentile
t each Charlson score (CAD-specific index worse); and
hose whose CAD-specific index scores fell below the
5th percentile (CAD-specific index better). Analyses
ere repeated using the full Charlson index (including
I and CHF) and a new CAD-specific index that
ncluded these terms.
ESULTS
total of 1,471 patients undergoing initial coronary an-
iography were included in the study and followed up for a
ean of 13.6 years. Through December 2000, there were
33 deaths, and the mean time to death was 11.4 years. The
linical characteristics of these patients are listed in Table 1.
he mean age at study entry was 60.9 years; 28% of the
atients were female, and 8% were African American.
ompared with patients without comorbid illnesses, those
ith one or more additional condition(s) were older and
ore likely to be female and had worse coronary disease
everity according to more diseased epicardial vessels and a
lightly lower mean LVEF.
The number of patients having each Charlson condition
s listed in Table 2. As expected with a cohort of CAD
atients, six of the seven most common conditions were risk
actors for or direct manifestations of vascular disease,
ncluding MI, diabetes mellitus, peripheral vascular disease,
HF, and cerebrovascular disease. No patients had acquired
mmunodeficiency syndrome (AIDS) or moderate to severe
iver disease at the time of coronary angiography. The
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CAD-Specific Comorbidity Index February 18, 2004:576–82reatest proportion of patients scored exhibited minimal
omorbid disease.
In a comparison of conditions in the newly derived
AD-specific index with those of the Charlson index, a
umber of conditions increased in relative importance,
ncluding moderate to severe renal disease, chronic pulmo-
ary disease, and peripheral vascular disease (Table 3).
ther conditions were not found to be significantly associ-
ted with long-term mortality in the coronary disease
opulation, including peptic ulcer disease, lymphoma, and
onnective tissue disease. For certain low-prevalence condi-
ions, such as dementia, mild liver disease, hemiplegia,
eukemia, moderate or severe liver disease, and AIDS,
onclusions could not be drawn. Of the four conditions
ested that were not specified by Charlson, ongoing tobacco
buse and hypertension were significantly associated with
urvival, whereas family history and hyperlipidemia were
ot. The distribution of Charlson and CAD-specific scores
or all patients is depicted in Table 4.
As shown by unadjusted Kaplan-Meier curves, both the
harlson index and CAD-specific index stratified patients
ccording to distinct survival patterns (Fig. 1). For the Charl-
on index, scores of 0, 1, and 2 yielded survival probabilities
f 88.3% (95% confidence interval [CI] 85.9% to 90.3%),
4.7% (80.6% to 87.9%), and 68.9% (63.2% to 73.9%),
espectively. For scores of 0 to 1, 2 to 3, and4, the respective
Table 1. Demographic and Characteristics of 1
Total
(n  1,471)
M
Age (yrs) 60.9  9.6
Female (%) 28.0
Race (%)
African American 8.0
White 90.9
Other 1.1
Hypertension (%) 55.7
Current smoking (%) 33.6
History of MI (%) 36.2
No. of diseased vessels (%)
1 31.0
2 30.5
3 38.5
CHF severity (%)
None 87.5
NYHA class I 2.86
NYHA class II 5.03
NYHA class III 3.26
NYHA class IV 1.36
Chest pain course (%)
Improving 5.57
Stable 34.66
Progressing 48.41
Unstable 11.36
Ejection fraction (%) 50.8  10.6
Data are presented as the mean value  SD or percentage o
CHF  congestive heart failure; MI  myocardial infarcve-year all-cause survival probabilities for the CAD index tere 89.2% (95% CI 86.9% to 91.1%), 81.6% (77.5% to
5.1%), and 67.9% (61.6% to 73.4%), respectively.
In proportional hazards models that adjusted for age,
ender, and LVEF, both the modified Charlson index and
he CAD-specific index were the strongest predictors of
ortality according to chi-square values for each term, with
Patients With Coronary Artery Disease
d Charlson
ex  0
574)
Modified Charlson
Index >0
(n  897) p Value
 9.8 62.0  9.3  0.001
5.4 31.2 0.02
0.34
8.3 7.8
0.9 90.7
0.8 1.5
2.8 59.3 0.01
2.7 34.6 0.44
4.2 38.6 0.09
 0.0001
5.4 25.6
0.1 31.0
4.5 43.4
0.001
0.4 84.0
2.35 3.48
4.44 5.75
2.22 4.54
0.62 2.27
0.28
6.28 4.74
6.05 33.02
7.13 49.92
0.55 12.32
 9.8 49.5  11.4  0.0001
nts.
YHA  New York Heart Association.
able 2. Number (%) of Patients With Each Condition
urrent smoker 494 (33.6%)
ypertension 820 (55.7%)
yocardial infarction 413 (28.1%)
iabetes mellitus (total) 268 (18.2%)
eptic ulcer disease 186 (12.6%)
eripheral vascular disease 118 (8.0%)
iabetes with end-organ damage 113 (7.7%)
ongestive heart failure 110 (7.5%)
erebrovascular disease 105 (7.1%)
hronic pulmonary disease 95 (6.5%)
ny tumor 29 (2.0%)
onnective tissue disease 23 (1.6%)
etastatic solid tumor 16 (1.1%)
oderate or severe renal disease* 13 (0.9%)
ementia 6 (0.4%)
emiplegia 4 (0.3%)
ild liver disease 4 (0.3%)
ymphoma 3 (0.2%)
eukemia 2 (0.1%)
oderate or severe liver disease 0
cquired immunodeficiency syndrome 0
Moderate renal disease includes patients with creatinine 3 mg/dl, whereas severe
enal disease includes patients on dialysis or those who have undergone kidney,471
odifie
Ind
(n 
60.1
2
9
5
3
3
3
3
3
9
3
4
1
51.8
f patieransplantation.
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February 18, 2004:576–82 CAD-Specific Comorbidity Indexhe CAD-specific index having the higher value (Table 5).
hen comparing the strength of association for the entire
odel, the model containing the CAD-specific index had a
tronger association according to a significantly higher
ikelihood ratio chi-square value (modified Charlson index
hi-square 243; CAD-specific index chi-square 277). When
aking a comparison between the two indexes, the CAD-
pecific index added significant prognostic information to a
odel containing the modified Charlson index (chi-square
34, p  0.0001), whereas the modified Charlson index
id not add significantly to a model containing the CAD-
pecific index (chi-square  0.8, p  0.36). When compar-
able 3. The Charlson Comorbidity Index as Compared With
he CAD-Specific Index
Charlson
Weights Conditions
CAD-Specific
Index
0 Current smoker 1
Hypertension 1
1 Myocardial infarction *
Dementia Limited cases†
Peptic ulcer disease Not significant‡
Congestive heart failure *
Connective tissue disease Not significant
Mild liver disease Limited cases
Cerebrovascular disease 1
Diabetes mellitus 2
Chronic pulmonary disease 2
Peripheral vascular disease 2
2 Hemiplegia Limited cases
Leukemia Limited cases
Any tumor 2
Diabetes with end-organ damage 3
Moderate or severe renal disease‡ 7
Lymphoma Not significant
3 Moderate or severe liver disease Limited cases
6 Acquired immunodeficiency syndrome Limited cases
Metastatic solid tumor 5
Myocardial infarction and congestive heart failure were excluded from the CAD
ndex, as these represent direct manifestations of coronary disease, rather than
omorbid illness. †Limited cases denotes that there were not enough cases in our data
et to reach a valid conclusion. ‡Not significant indicates that our models revealed
hese diseases were “not significantly” associated with survival. ‡Moderate renal
isease includes patients with creatinine of 3 mg/dl, whereas severe renal disease
ncludes patients on dialysis or those who have undergone kidney transplantation.
CAD  coronary artery disease.
able 4. Frequency of Scores by the Charlson and CAD-
pecific Indexes
Charlson Index Index Score CAD-Specific Index
810 (55%) 0 286 (19%)
378 (26%) 1 539 (37%)
187 (13%) 2 220 (15%)
63 (4%) 3 183 (12%)
15 (1%) 4 133 (9%)
0 5 60 (4%)
12 (0.8%) 6 23 (1.6%)
5 (0.3%) 7 10 (0.7%)
1 (0.07%) 8 8 (0.5%)
0 9 4 (0.3%)
0 10 0
0 11 5 (0.3%)tAD  coronary artery disease.ng the overall indexes with their individual components,
he addition of the component conditions of the Charlson
ndex to a model containing the overall index had a
ignificantly greater association with prognosis, further sug-
esting that the Charlson scores should be reweighted for
ur population to obtain a better estimate of survival
chi-square  39, p  0.0001). The addition of the
omponents of the CAD-specific index to a model contain-
ng the overall index did not change the association with
urvival, indicating appropriate weights for our population
chi-square  6.0, p  0.92).
Figure 2 shows actual and predicted five-year survival for
roups of patients stratified by index scores for both the
harlson and CAD-specific indexes. Both indexes showed
ood calibration with all points falling close to the line of
erfect agreement. When considering discrimination ac-
ording to c indexes for five-year survival predictions, both
odels yielded similar values (0.72 and 0.73, respectively).
hese values indicate that for all potential pairs of patients
ho either survived or died by five years, the proportional
azards models assigned greater risk approximately 73% of
igure 1. Kaplan-Meier survival curves for the Charlson and coronary
rtery disease (CAD) indexes. Patients were classified by their score, such
hat each graph depicts a similar number of patients in a particular risk
ategory. There are approximately 55% of patients in the lowest risk group
Charlson score  0; CAD score  0 to 1), 25% at intermediate risk
Charlson score  1; CAD score  2 to 3), and 20% at highest risk
Charlson score  2; CAD score  4). Both indexes stratify risk well.he time to those who died.
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CAD-Specific Comorbidity Index February 18, 2004:576–82Our final comparison examined survival for patients in
hom the two indexes disagreed. For patients whose CAD-
pecific index score was above the 75th percentile at each given
evel of the Charlson index (higher risk), Kaplan-Meier curves
emonstrated worse survival than for patients whose CAD-
pecific index and Charlson index agreed. Conversely, for
atients whose CAD-specific index score fell below the 25th
ercentile, Kaplan-Meier curves also showed worse survival
han for those in an intermediate range, though survival was
ot quite as poor for those in the higher CAD-specific index
Table 5. Cox Linear Regression Models
Parame
Estim
Model 1: chi-square  243.3, df  5*
Modified Charlson index† 0.3
Age 62 yrs 0.0
Age 62 yrs 0.0
Female 0.0
Ejection fraction (%) 0.0
Model 2: chi-square  276.7, df  5*
CAD-specific index‡ 0.3
Age 62 yrs 0.0
Age 62 yrs 0.0
Female 0.0
Ejection fraction (%) 0.0
*Two different slopes were used in both models 1 and 2 to re
the hazard increases 4% for every 1-year increase in age; for pa
increase in age. †Modified Charlson index is the sum of orig
heart failure removed. ‡CAD-specific index is the sum of ne
and congestive heart failure removed.
CAD  coronary artery disease; CI  confidence interva
igure 2. Actual versus predicted survival by each index. Both indexes
how good calibration, with most points falling close to the line of perfect
greement. The coronary artery disease (CAD) index performed slightlyCetter, as evidence by an improved c index.ange. Thus, when the Charlson index and CAD-specific
ndex disagreed, patients appeared to have higher mortality,
orrelating with the index that portended a worse prognosis.
mong the discordant groups, a higher CAD-specific index
as associated with the worst survival.
When analyses were repeated after including all Charlson
onditions, including MI and CHF, the same trends were
bserved regarding the strength of association, calibration,
iscrimination, and outlier analyses.
ISCUSSION
his study demonstrates that comorbid illness, or illnesses
hat co-exist with coronary disease, is strongly associated
ith long-term survival. In proportional hazards models
xamining patients in the Duke Databank for Cardiovascu-
ar Diseases, the strength of this association between co-
orbid illness and survival was almost equivalent to that
fforded by standard measures of coronary disease severity,
ncluding LVEF. These findings indicate that comorbid
llness must be taken into account when considering the
ong-term benefit of coronary disease therapies in clinical
rials, disease registries, quality comparisons, and counseling
f individual patients. These findings are particularly im-
ortant to the elderly, given their high prevalence of
o-existing illness and the increasing numbers of elderly
atients facing treatment decisions for CAD.
A second remarkable finding of this study was the relative
tability of the prognostic significance of the Charlson comor-
idity index among CAD patients. We were surprised to find
hat a measure of comorbid illness, based on one-year mortal-
ty, for 559 New York University general medicine patients
ould have an association with long-term survival similar to an
ndex specifically developed and weighted to our CAD popu-
ation. Our findings did suggest some modifications to the
harlson index that may make this measure more suitable to
Standard
Error p Value
Hazard Ratio
(95% CI)
0.04  0.0001 1.41 (1.30–1.53)
0.01 0.0015 1.04 (1.01–1.06)
0.01  0.0001 1.08 (1.06–1.10)
0.12 0.7151 0.957 (0.75–1.21)
0.01  0.0001 0.95 (0.94–0.96)
0.03  0.0001 1.34 (1.27–1.42)
0.01 0.0026 1.04 (1.01–1.06)
0.01  0.0001 1.10 (1.07–1.12)
0.12 0.6675 0.95 (0.75–1.20)
0.01  0.0001 0.95 (0.94–0.96)
t the age effect. In model 1, for patients with age 62 years,
with age62 years, the hazard increases 8% for every 1-year
harlson weights, with myocardial infarction and congestive
ghts from the CAD population, with myocardial infarction
degrees of freedom.ter
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February 18, 2004:576–82 CAD-Specific Comorbidity Indexeight to renal disease, diabetes with end-organ damage,
hronic obstructive pulmonary disease, and peripheral vascular
isease, as well as dropping some conditions from consider-
tion due to their lack of prognostic significance (peptic ulcer
isease, lymphoma, connective tissue disease) or low prevalence
dementia, liver disease, hemiplegia, leukemia, and AIDS)
mong CAD patients being considered for revascularization.
The highly significant correlation between comorbid illness
nd prognosis observed among our CAD patients has been
reviously investigated. Several previous studies have docu-
ented increased mortality among persons with specific index
onditions. From the Framingham Study, we know that
iabetics suffer worse outcomes than nondiabetics (9). Inves-
igators have demonstrated through the use of the Coronary
rtery Surgery Study (CASS) registry that patients with
eripheral vascular disease and ongoing tobacco abuse have
hortened long-term survival, whereas those with hyperlipid-
mia are unaffected (10–12). Shlipak et al. (13) examined over
00,000 patients and established renal disease as an indepen-
ent risk factor for death after MI.
The philosophy of a score such as the Charlson index is
o account for illnesses other than the condition of interest
n comparisons of treatment and outcome. There is, how-
ver, some overlap in etiology and disease progression
etween the elements of our comorbidity index and the
rimary disease of interest. For example, peripheral vascular
isease and cerebrovascular disease may be considered man-
festations of underlying “vascular disease” that has pro-
ressed to affect multiple territories rather than distinct
omorbid illnesses. Given this overlap, some components of
ur index may be considered to represent “disease staging”
ather than wholly separate disease entities.
linical significance. These findings can be applied to a
umber of settings. Our study identifies, among CAD pa-
ients, prevalent and prognostically important co-existing ill-
esses that should be measured and considered in clinical trials
nd coronary disease registries regarding medical therapeutics.
hey also suggest that whenever possible, clinical trials should
nclude subjects with significant comorbid illness, such as renal
nsufficiency, diabetes with end-organ damage, and chronic
ulmonary disease, so that their results may be extrapolated to
he entire spectrum of CAD patients.
Prognostic indexes regarding comorbid illness are also an
ssential component of quality assessment of health care
roviders. To derive fair inferences regarding mortality and
rocess of care, comparisons must be balanced for prognos-
ically important differences in patient characteristics. Both
he CAD-specific index and the Charlson index can be
mployed in risk adjustment. In the case of studies involving
relatively small number of patient outcomes, these indexes
hould be entered as a single value to account for comor-
idity. This approach of using a single comorbidity index
educes the number of candidate variables and the potential
or identifying spurious associations. In the case of large
tudies involving substantially more outcome events, the
omponent variables from either index should be addedeparately, independent of their index weights, such that the
elative importance of each illness will be specifically ad-
usted to the data set of interest.
A final application of these data involves the consider-
tion of medical evidence for individual patients at the
edside. Illnesses that are likely to significantly limit life-
xpectancy, such as renal disease and diabetes with end-
rgan damage, should be taken into consideration when
iscussing the long-term ramifications of CAD therapies.
hese indexes also identify high-risk patients in whom
ggressive therapies may be targeted.
tudy limitations. A limitation of both this study and the
riginal comorbidity review by Charlson is the dependence
n chart review to ascertain the presence of comorbidity (2).
s with any retrospective study, the individuals initially
ecording the patient’s history were not aware of our
esearch question or comorbidity definitions. Therefore,
ome pertinent information on comorbid illness may not
ave been recorded or may have been recorded incorrectly.
or this study, we operated with the conservative assump-
ion that a condition was not present unless it had been
ocumented. The effect of such an assumption would be to
ttribute a lack of illness in some patients, possibly incor-
ectly, thus diminishing the difference in comorbidity levels.
f comorbidity information had been collected prospec-
ively, we would expect the relationship between the CAD-
pecific index and mortality to be even greater.
onclusions. We found that co-existing illness, or comor-
idity, was strongly associated with long-term survival
mong CAD patients. The strength of this association was
lmost equivalent to that of standard CAD severity mea-
ures, including LVEF. This study also found that the
ong-established Charlson comorbidity index had a prog-
ostic significance remarkably similar to that of a comor-
idity measure specifically developed for our CAD popula-
ion. Co-existing illnesses identified by this study that are
revalent and prognostically important should be taken into
ccount when considering the long-term benefit of coronary
isease therapies in clinical trials, disease registries, cohort
tudies, and advice to individual patients.
eprint requests and correspondence: Dr. Molly Sachdev,
uke University, Internal Medicine, 129 Forest Oaks, Durham,
orth Carolina 27705. E-mail: mollysachdev@yahoo.com.
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